<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03566316</url>
  </required_header>
  <id_info>
    <org_study_id>ID-TAR-301</org_study_id>
    <nct_id>NCT03566316</nct_id>
  </id_info>
  <brief_title>Efficacy/Safety of Telmisartan/Amlodipine/Rosuvastatin in Hypertensive Patients With Hyperlipidemia</brief_title>
  <official_title>Randomized, Double-blind, Multi-center Phase III Clinical Trial to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine and Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IlDong Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IlDong Pharmaceutical Co Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Double-blind, Multi-center Phase III Clinical Trial to Evaluate the Efficacy
      and Safety of Telmisartan/Amlodipine and Rosuvastatin Co-administration in Hypertensive
      Patients with Hyperlipidemia
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 24, 2015</start_date>
  <completion_date type="Actual">June 16, 2017</completion_date>
  <primary_completion_date type="Actual">June 16, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of change in LDL-Cholesterol</measure>
    <time_frame>From baseline at week 8</time_frame>
    <description>Telmisartan/Amlodipine/Rosuvastatin versus Telmisartan/Amlodipine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change of sitting systolic blood pressure</measure>
    <time_frame>From baseline at week 8</time_frame>
    <description>Telmisartan/Amlodipine/Rosuvastatin versus Telmisartan/Rosuvastatin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of change in LDL-Cholesterol</measure>
    <time_frame>From baseline at week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of change in HDL-Cholesterol, total Cholesterol, Triglyceride, Apolipoprotein B</measure>
    <time_frame>From baseline at week 4 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of HDL-Cholesterol/LDL-Cholesterol ratio</measure>
    <time_frame>From baseline at week 4 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of total cholesterol/HDL-Cholesterol ratio</measure>
    <time_frame>From baseline at week 4 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients reaching treatment goals according to National Cholesterol Education Program-Adults Treatment Panel III Guideline</measure>
    <time_frame>From baseline at week 4 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of sitting diastolic blood pressure</measure>
    <time_frame>From baseline at week 4 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients reaching treatment goals according to Joint National Committee VIII Guideline</measure>
    <time_frame>From baseline at week 4 and 8</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Hypertension With Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Telmisartan/Amlodipine+Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan/Amlodipine 40/5mg 2tab., Rosuvastatin 20mg1tab. and Telmisartan placebo 1tab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan/Amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Telmisartan/Amlodipine 40/5mg 2tab., Rosuvastatin placebo 1tab. and Telmisartan placebo 1tab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan +Rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Telmisartan/Amlodipine placebo 2tab., Rosuvastatin 80mg 1tab. and Telmisartan 20mg 1tab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan/Amlodipine</intervention_name>
    <arm_group_label>Telmisartan/Amlodipine</arm_group_label>
    <arm_group_label>Telmisartan/Amlodipine+Rosuvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <arm_group_label>Telmisartan +Rosuvastatin</arm_group_label>
    <arm_group_label>Telmisartan/Amlodipine+Rosuvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <arm_group_label>Telmisartan +Rosuvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 19 years old or above

          2. Patients who confirmed essential hypertension with Hyperlipidemia or use of drugs at
             Visit 1 (sit systolic blood pressure ≥ 140mmHg, LDL-Cholesterol ≥ 100mg/dL)

          3. Patients who can stop the treatment of anti-hypertensive/anti-hyperlipidemic drugs in
             the opinion of the investigator

          4. Test results showing the following values at screening time (Visit 2) : sit systolic
             blood pressure &gt;140mmHg

          5. Test results showing the following values at screening time (Visit 2) : 100&lt;
             LDL-Cholesterol &lt;250

          6. Patients who agreed to participate in the trial

        Exclusion Criteria:

          1. Severe hypertension patients(systolic blood pressure ≥ 180 mm Hg or diastolic blood
             pressure ≥ 110 mm Hg)

             -The change of mean sit systolic blood pressure ≥ 20 mmHg or sit diastolic blood
             pressure ≥ 10 mmHg on target arm between 1st and 2nd measurement

          2. LDL-Cholesterol &gt; 250 mg/dL or triacylglycerol ≥ 400 mg/dL at screening time(Visit 1)

          3. Patients with postural hypotension who have sign and symptom

          4. Patients with secondary blood pressure(for example,aortic coarctation,
             hyperaldosteronism, renal artery stenosis, Cushing's syndrome, pheochromocytoma,
             Polycystic Kidney Diseases)

          5. Patients with congestive heart failure(New York Heart Association class III~IV)

          6. Patients with history of acute coronary syndrome or underwent revascularization
             (percutaneous transluminal coronary angioplasty or Coronary Artery Bypass Graft
             surgery ) within 6 months

          7. Patients who have severe ventricular tachycardia, atrial fibrillation, atrial flutter
             or clinically significant arrhythmia

          8. Causes of hemodynamic disorder or structural heart defect such as valvular heart
             disease

          9. Patients who have history of cerebrovascular disease as cerebral infarction, cerebral
             hemorrhage within 6 months prior to study entry

         10. Patients with primary aldosteronism

         11. Patients with severe ocular disorders

         12. Patients with autoimmune disease

         13. Patients with any chronic inflammation disease needed to chronic inflammation therapy

         14. Patients with uncontrolled diabetes Mellitus with HbA1c &gt; 9% or thyroid diseases(TSH ≥
             1.5 X ULN)

         15. Patients who have a history of myopathy or rhabdomyolysis

         16. Patients who have 3 times of upper limit of normal range of muscle enzyme (creatinine
             kinase, CK)

         17. History of malignant tumor including leukemia, lymphoma within 5 years

         18. Patients with one kidney

         19. Patients with biliary obstructive disorder

         20. Patients with clinically significant electrolyte disturbance

         21. Continued serum potassium concentration abnormal status (&lt;3.5mEq/L or &gt;5.5mEq/L)

         22. Patients with sodium ion or body fluid is depleted and not able to correct

         23. Patients with clinically significant liver/renal disease

         24. Patients with digestive diseases that may affect the absorption or history in
             gastrointestinal surgery

         25. Patients who are dependent on drugs or alcohol

         26. Pregnancy, breast-feeding, or child-bearing potential Patients

         27. Patients with hypersensitivity to telmisartan or other angiotensin II receptor
             blockers

         28. Patients with hypersensitivity to Amlodipine or other dihydropyridine drugs

         29. Patients with history of Myotoxicity to other 3-hydroxy-methyl glutaryl-coenzyme A
             reductase inhibitor or fibrate

         30. Patients who are unable to stop taking prohibited drugs to combination during study
             period

         31. Patients who have galactose intolerance

         32. Patients taking other clinical trial drugs within 30 days from the time of visit for
             screening

         33. Patients that is not eligible to participate at the discretion of study investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 11, 2018</study_first_submitted>
  <study_first_submitted_qc>June 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2018</study_first_posted>
  <last_update_submitted>June 20, 2018</last_update_submitted>
  <last_update_submitted_qc>June 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Telmisartan amlodipine combination</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

